Souhaitez-vous accéder aux communiqués récents ?

The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to invobenitug (procizumab) for the treatment of cardiogenic shock.

Results presented by the LiBBY study team at the Alzheimer’s Association International Conference (“AAIC”) demonstrated statistically significant improvements in agitation symptoms compared with...

First patient treated in Phase 2 A-TANGO trial of innovative combination treatment for acute-on-chronic liver failure

PORTLAND, Ore., July 09, 2026 (GLOBE NEWSWIRE) -- VisCardia, Inc. today announced the first U.S. patient has been implanted in its RECOVER-HF pivotal trial of VisONE™ Synchronized Diaphragmatic...

Both parties intend to approach the collaboration in a spirit of openness, scientific rigor, and shared problem-solving, with the goal of advancing PRP

Phase 3 EPIDYS MRI data quantify givinostat’s potential to preserve functional muscle tissue and reduce fat infiltration in patients with Duchenne muscular dystrophy1Updated open-label extension data...

SkinTE® would be the first new biologic commercially available in the U.S. for the treatment of a common chronic wound indication in nearly 30 years, if approved. SkinTE® is a first-in-class...

MedTech BellaSeno is accelerating human trials of its proprietary breast scaffolds as it moves regenerative breast surgery toward clinical adoption.

AdJane Reports First Clinical Validation of its OMV Vaccine Platform Inducing Mucosal Immunity in Humans

Résultats positifs de la partie 2 de l’essai de maintenance ABTECT démontrant un bénéfice clinique significatif chez des patients atteints de RCH réfractaire et renforçant les données de sécurité ...